Low dose cytarabine monotherapy for myelodysplastic syndromes
نویسندگان
چکیده
منابع مشابه
Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
BACKGROUND In order to assess the role of the combination of low-dose cytarabine (Ara-C) plus aclarubicin (CA) in remission induction for patients with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), we retrospectively analyzed the efficacy and safety of CA. PATIENTS AND METHODS Data of twenty patients with untreated AML or high-risk MDS who were ineligible...
متن کاملMyelodysplastic Syndromes Myelodysplastic syndromes: recent advances
Etiology of myelodysplastic syndromes The models for the development of sporadic MDS suggest the role of cumulative environmental exposures in genetically predisposed individuals. There is increasing evidence for a complex genetic predisposition to MDS involving naturally occurring DNA polymorphisms in genes that mediate DNA repair and metabolize environmental carcinogens.3 Large epidemiologic ...
متن کاملCombined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
BACKGROUND Low-dose cytarabine (ara-C) has been used to treat older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), but has resulted in complete remission for <20% of cases. A pilot study of the efficacy of a combination chemotherapy using low-dose ara-C, melphalan (Mel), and mitoxantrone (Mit) was conducted. PATIENTS AND METHODS The treatment comprised...
متن کاملDiagnostic flow cytometry for low-grade myelodysplastic syndromes.
It has long been considered that flow cytometry (FCM) has little role in clinical practice in the diagnosis of myelodysplastic syndromes (MDS). However, recent advances in the analytical method and knowledge of MDS FCM are changing this stereotype. This paper reviews the concept and current status of FCM in the diagnosis of low-grade MDS. The diagnosis of low-grade MDS in the absence of ringed ...
متن کاملMyelodysplastic syndromes.
The myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders characterized by dysplastic and ineffective hematopoiesis and a varying risk of transformation to acute leukemia. Although the natural history of these syndromes is variable, several factors appear to be of prognostic importance, including the French-American-British classification, the karyotype, in vi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2016
ISSN: 1465-1858
DOI: 10.1002/14651858.cd009499.pub2